Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncogene
Main Authors: Yang, H, Kircher, D A, Kim, K H, Grossmann, A H, VanBrocklin, M W, Holmen, S L, Robinson, J P
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2017
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/
https://ncbi.nlm.nih.gov/pubmed/28263969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker